Clinical Trials | August 04, 2022
Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.
Dxcover announced that it will be presenting new data at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 3-7
City of Hope is first in world to test oncolytic virus, CF33-hNIS, in people with metastatic solid tumours
Erytech is evaluating valuable strategic options to leverage its Erycaps platform and its development and manufacturing capabilities with complementary assets and/or a broader corporate transaction
In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
Cantex also plans to initiate Phase 2 clinical trials exploring the therapeutic effect of azeliragon in pancreatic and breast cancers.
The facility will manufacture its Herceptin biosimilar, Tuznue
Collaboration aims to evolve precision medicine with cell-specific delivery of gene therapy
APS03118 is a novel innovative drug developed by APS with global independent intellectual property rights for unlimited cancer types
It is indicated for the treatment of patients with acromegaly and Gastroenteropancreatic Neuroendocrine Tumours
Subscribe To Our Newsletter & Stay Updated
